Literature DB >> 33994645

Geographical Overlap Between Alpha-1 Antitrypsin Deficiency and COVID-19 Infection in Italy: Casual or Causal?

Andrea Vianello1, Fausto Braccioni1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33994645      PMCID: PMC7489245          DOI: 10.1016/j.arbr.2020.05.011

Source DB:  PubMed          Journal:  Arch Bronconeumol (Engl Ed)        ISSN: 0300-2896            Impact factor:   4.872


× No keyword cloud information.
Dear Editor: At the time when WHO reports that Italy is currently the fifth country in the world for number of cases of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection (225,886 confirmed positive cases to 19th May 2020), and the third country for number of related deaths (32,007 fatal cases), it is important to underline that the distribution of affected subjects in our country is very inhomogeneous. 85% of total fatal cases have been registered, in fact, in the Northern Italy (in particular 37.8% in the Lombardia region), with an abrupt decrease from north to south (Fig. 1 ). This geographic difference is still difficult to understand and many factors may account for it.
Fig. 1

Distribution of confirmed cases of Alpha-1 antitrypsin deficiency and Severe Acute Respiratory Syndrome Coronavirus-2 infection in Italy to 18th April 2020 (AATD = alpha-1 antitrypsin deficiency; SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus-2).

Distribution of confirmed cases of Alpha-1 antitrypsin deficiency and Severe Acute Respiratory Syndrome Coronavirus-2 infection in Italy to 18th April 2020 (AATD = alpha-1 antitrypsin deficiency; SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus-2). α1-Antitrypsin (AAT) is a serine protease inhibitor whose primary function is to counterbalance the proteolytic action of human neutrophil elastase in the lungs. An autosomal codominant disorder, AAT deficiency (AATD) is characterized by reduced serum level or abnormal function of AAT, that increases the risk of developing a variety of diseases, including pulmonary emphysema and liver cirrhosis. The most common hereditary disorder in adults, AATD was found to have the highest prevalence rates in northern regions of Italy and to decrease very fast from north to south. Recent data from the Italian Registry for AATD, showed a geographic distribution of confirmed cases very similar to the one reported for SARS-CoV-2 infection, with 47% of the total amount registered in the Lombardia region (237 out of 508) (Fig. 1). Although population size is much smaller than the SARS-CoV-2 patient population, it is noteworthy that AATD is largely under-recognized in our country, with a relation between diagnosed and expected cases of 1–460. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. A recent study demonstrated that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. Moreover, the Authors reported that a TMPRSS2 inhibitor approved for clinical use blocked viral entry. Based on these results, we argue that a protease-antiprotease imbalance could play a central role in the pathogenicity and virulence of SARS-CoV-2 and we hypothesize that the high prevalence of AATD could have contributed to the devastating impact of coronavirus infection in the Northern Italy. Could causality and not casualness explain geographical overlap between AATD and COVID-19 infection in our country? A detailed analysis of data from the Italian Registry will give us an answer.

Funding

This work was not funded by any organization.

Conflict of interest

None declared.
  3 in total

1.  Italian registry of patients with alpha-1 antitrypsin deficiency: general data and quality of life evaluation.

Authors:  Maurizio Luisetti; Ilaria Ferrarotti; Luciano Corda; Stefania Ottaviani; Nuccia Gatta; Carmine Tinelli; Gisella Bruletti; Enrica Bertella; Gianluigi Balestroni; Marco Confalonieri; Christine Seebacher; Leonardo Iannacci; Simona Ferrari; Francesco G Salerno; Frescesca Mariani; Mauro Carone; Bruno Balbi
Journal:  COPD       Date:  2015-05       Impact factor: 2.409

2.  Genetic epidemiology of alpha-1 antitrypsin deficiency in southern Europe: France, Italy, Portugal and Spain.

Authors:  F J de Serres; I Blanco; E Fernández-Bustillo
Journal:  Clin Genet       Date:  2003-06       Impact factor: 4.438

3.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

  3 in total
  17 in total

Review 1.  Neutrophil Extracellular Traps (NETs) in Severe SARS-CoV-2 Lung Disease.

Authors:  Monika Szturmowicz; Urszula Demkow
Journal:  Int J Mol Sci       Date:  2021-08-17       Impact factor: 5.923

2.  Alpha-1 Antitrypsin Deficiency and COVID-19 Infection.

Authors:  Michael Strassmair; Manfred Stangl
Journal:  Arch Bronconeumol       Date:  2020-10-22       Impact factor: 4.872

3.  Epidemiological correlation between COVID-19 epidemic and prevalence of α-1 antitrypsin deficiency in the world.

Authors:  Hiroshi Yoshikura
Journal:  Glob Health Med       Date:  2021-04-30

4.  Insights into the potential role of alpha1-antitrypsin in COVID-19 patients: Mechanisms, current update, and future perspectives.

Authors:  Saber Marzouk; Noha Attia; Mohamed Mashal
Journal:  Clin Respir J       Date:  2021-07-12       Impact factor: 1.761

Review 5.  Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.

Authors:  Xiyuan Bai; Joseph Hippensteel; Alida Leavitt; James P Maloney; David Beckham; Cindy Garcia; Qing Li; Brian M Freed; Diane Ordway; Robert A Sandhaus; Edward D Chan
Journal:  Med Hypotheses       Date:  2020-11-12       Impact factor: 1.538

6.  Host genomics of COVID-19: Evidence point towards Alpha 1 antitrypsin deficiency as a putative risk factor for higher mortality rate.

Authors:  Atanu Kumar Dutta; Kalyan Goswami
Journal:  Med Hypotheses       Date:  2021-01-09       Impact factor: 1.538

7.  Air pollutants and risk of death due to COVID-19 in Italy.

Authors:  Marco Dettori; Giovanna Deiana; Ginevra Balletto; Giuseppe Borruso; Beniamino Murgante; Antonella Arghittu; Antonio Azara; Paolo Castiglia
Journal:  Environ Res       Date:  2020-11-11       Impact factor: 6.498

Review 8.  Does Genetic Predisposition Contribute to the Exacerbation of COVID-19 Symptoms in Individuals with Comorbidities and Explain the Huge Mortality Disparity between the East and the West?

Authors:  Naoki Yamamoto; Rain Yamamoto; Yasuo Ariumi; Masashi Mizokami; Kunitada Shimotohno; Hiroshi Yoshikura
Journal:  Int J Mol Sci       Date:  2021-05-08       Impact factor: 5.923

9.  Ethnic differences in alpha-1 antitrypsin deficiency allele frequencies may partially explain national differences in COVID-19 fatality rates.

Authors:  Guy Shapira; Noam Shomron; David Gurwitz
Journal:  FASEB J       Date:  2020-09-22       Impact factor: 5.191

Review 10.  Alpha-1-antitrypsin: A possible host protective factor against Covid-19.

Authors:  Mariana Braccialli de Loyola; Thaís Tereza Aguiar Dos Reis; Guilherme Xavier Lyra Malcher de Oliveira; Julys da Fonseca Palmeira; Gustavo A Argañaraz; Enrique R Argañaraz
Journal:  Rev Med Virol       Date:  2020-08-26       Impact factor: 11.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.